|
Dec 05, 2022
|
Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
|
|
|
Dec 02, 2022
|
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program
|
|
|
Nov 09, 2022
|
Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights
|
|
|
Nov 07, 2022
|
Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting
|
|
|
Nov 02, 2022
|
Nkarta to Participate at Upcoming Investor Conferences
|
|
|
Aug 11, 2022
|
Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights
|
|
|
Jul 25, 2022
|
Nkarta Announces Key Senior Leadership Team Appointments
|
|
|
May 31, 2022
|
Nkarta to Participate at Upcoming Investor Conference
|
|
|
May 16, 2022
|
Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development
|
|
|
May 12, 2022
|
Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights
|
|
